Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 243Stomach Neoplasms 23Breast Neoplasms, Male 16Neoplasm Metastasis 14Neoplasms 8Inflammatory Breast Neoplasms 8Esophageal Neoplasms 8Brain Neoplasms 8Colorectal Neoplasms 6Adenocarcinoma Of Esophagus 4Urologic Neoplasms 3Triple Negative Breast Neoplasms 3HER2-positive Breast Cancer 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Ductal, Breast 3Gallbladder Neoplasms 2Endometrial Neoplasms 2Cholangiocarcinoma 2Carcinoma, Lobular 2Carcinoma, Intraductal, Noninfiltrating 2Biliary Tract Neoplasms 2Adenocarcinoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Solid Cancers 1Rectal Neoplasms 1Prostatic Neoplasms 1Patient Preference 1Patient Compliance 1

Interventions

Specimen Handling 3Biopsy 3X-Rays 2trastuzumab biosimilar HLX02 1pertuzumab 1erdafitinib 1copanlisib 1Trastuzumab 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Iopamidol 1CT-P6 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Malignant Solid Neoplasm × Trastuzumab × Clear all
NCT06136897 2026-05-29

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡